Curis Inc
CUS0
Company Profile
Business description
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Contact
128 Spring Street
Building C - Suite 500
LexingtonMA02421
USAT: +1 617 503-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
33
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,399.80 | 30.50 | 0.36% |
| CAC 40 | 7,696.92 | 31.01 | -0.40% |
| DAX 40 | 23,249.65 | 94.89 | -0.41% |
| Dow JONES (US) | 40,829.00 | 389.83 | -0.95% |
| FTSE 100 | 8,597.42 | 1.07 | 0.01% |
| HKSE | 22,773.95 | 111.24 | 0.49% |
| NASDAQ | 17,689.66 | 154.58 | -0.87% |
| Nikkei 225 | 36,843.52 | 12.83 | 0.03% |
| NZX 50 Index | 12,489.37 | 68.28 | 0.55% |
| S&P 500 | 5,606.91 | 43.47 | -0.77% |
| S&P/ASX 200 | 8,181.70 | 30.30 | 0.37% |
| SSE Composite Index | 3,337.23 | 21.11 | 0.64% |